Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-15T15:20:28.103Z Has data issue: false hasContentIssue false
  • English
  • Français

Psychiatric phenomena as initial manifestation of encephalitis by anti‐NMDAR antibodies

Published online by Cambridge University Press:  22 February 2013

Peter Maat ,
Esther de Graaff ,
Nico M. van Beveren ,
Esther Hulsenboom ,
Robert M. Verdijk ,
Kathelijne Koorengevel ,
Martijn van Duijn ,
Herbert Hooijkaas ,
Casper Hoogenraad  and
Peter A. Sillevis Smitt
Peter Maat
Affiliation:
Department of Neurology, Erasmus University Medical Center, Rotterdam, Netherlands
Esther de Graaff
Affiliation:
Department of Neurology, Erasmus University Medical Center, Rotterdam, Netherlands Department of Neurosciences, Erasmus University Medical Center, Rotterdam, Netherlands
Nico M. van Beveren
Affiliation:
Department of Psychiatry, Erasmus University Medical Center, Rotterdam, Netherlands
Esther Hulsenboom
Affiliation:
Department of Neurology, Erasmus University Medical Center, Rotterdam, Netherlands
Robert M. Verdijk
Affiliation:
Department of Pathology, Erasmus University Medical Center, Rotterdam, Netherlands
Kathelijne Koorengevel
Affiliation:
Department of Psychiatry, Erasmus University Medical Center, Rotterdam, Netherlands
Martijn van Duijn
Affiliation:
Department of Neurology, Erasmus University Medical Center, Rotterdam, Netherlands
Herbert Hooijkaas
Affiliation:
Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands
Casper Hoogenraad
Affiliation:
Department of Neurosciences, Erasmus University Medical Center, Rotterdam, Netherlands
Peter A. Sillevis Smitt*
Affiliation:
Department of Neurology, Erasmus University Medical Center, Rotterdam, Netherlands
*
Peter A. Sillevis Smitt, Department of Neurology, Erasmus University Medical Center, Erasmus MC room H639, s‐Gravendijkwal 230, 3015 CE Rotterdam, Netherlands. Tel: +31-10-7034415; Fax: +31-10-7033208; E‐mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Autoimmune encephalitis associated with autoantibodies against the N‐methyl‐d‐aspartate receptor (NMDAR) often presents with behavioural change. Our objective was to describe in detail the psychiatric presentation and pathways to care in order to aid the early diagnosis of NMDAR encephalitis.

Methods

Sera and cerebrospinal fluid (CSF) from patients with suspected NMDAR encephalitis were tested on HEK 293 cells transfected with the NR1 subunit of the NMDAR. Clinical information was obtained from the referring psychiatrists and neurologists and by review of the clinical records.

Results

Samples from 15 patients (13 female, 2 male, mean age 24 years, range 5–56 years) tested anti‐NMDAR positive. Twelve of the 15 patients (80%) presented with prominent psychiatric symptoms and 8 were initially referred to a psychiatric service. The most prominent initial psychiatric symptoms were anxiety in seven (47%), behavioural change (often bizarre) in six (40%) and agitation in five (33%). All patients developed psychiatric symptoms in the first 6 weeks of illness. Thirteen patients received psychotropic medications: antipsychotics in 12 and benzodiazepines in 11. Treating physicians considered the psychotropic medication not effective in 11 patients resulting in many drug switches. At nadir, all patients were in a very poor condition. However, eight patients (53%) recovered (almost) completely. Outcome tended to be better in patients who had received early immunotherapy or tumour removal.

Conclusions

Autoimmune encephalitis and anti‐NMDAR testing in serum and CSF should be considered in patients, especially young females, presenting with atypical psychiatric phenomena. Early diagnosis and treatment will likely improve the prognosis of NMDAR encephalitis.

Keywords

anti‐NMDAR antibodiesanti‐NMDAR encephalitispsychotic disorders
Type
Original Articles
Information
Acta Neuropsychiatrica , Volume 25 , Issue 3 , June 2013 , pp. 128 - 136
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Peery, HE, Day, GS, Dunn, S et al. Anti‐NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun Rev 2012. [Epub ahead of print; DOI:10.1016/j.autrev.2012.03.001].CrossRefGoogle ScholarPubMed
2Dalmau, J, Lancaster, E, Martinez‐Hernandez, E et al. Clinical experience and laboratory investigations in patients with anti‐NMDAR encephalitis. Lancet Neurol 2011;10:63–74.Google Scholar
3Dalmau, J, Tüzün, E, Wu, H et al. Paraneoplastic anti‐N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25–36.CrossRefGoogle ScholarPubMed
4Dalmau, J, Gleichman, A, Hughes, E et al. Anti‐NMDA‐receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–1098.Google Scholar
5Irani, SR, Bera, K, Waters, P et al. N‐methyl‐D‐aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non‐paraneoplastic disorder of both sexes. Brain 2010;133:1655–1667.Google Scholar
6Dale, RC, Irani, SR, Brilot, F et al. N‐methyl‐D‐aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol 2009;66:704–709.Google Scholar
7Florance, N, Davis, R, Lam, C et al. Anti‐N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66:11–18.Google Scholar
8Titulaer, M, Mccracken, L, Gabilondo Cuellar, I et al. Clinical features, treatment, and outcome of 500 patients with anti‐NMDA receptor encephalitis (PL01.001). Neurology 2012;78:PL01.001.Google Scholar
9Florance, NR, Davis, RL, Lam, C et al. Anti‐N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66:11–18.Google Scholar
10Hughes, EG, Peng, X, Gleichman, AJ et al. Cellular and synaptic mechanisms of anti‐NMDA receptor encephalitis. J Neurosci 2010;30:5866–5875.Google Scholar
11Zuliani, L, Graus, F, Giometto, B et al. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry 2012;83:638–645.Google Scholar
12Lancaster, E, Dalmau, J. Neuronal autoantigens‐pathogenesis, associated disorders and antibody testing. Nat Rev Neurol 2012;8:380–390.Google Scholar
13Chapman, MR, Vause, HE. Anti‐NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment. Am J Psychiatry 2011;168:245–251.Google Scholar
14Zandi, MS, Irani, SR, Lang, B et al. Disease‐relevant autoantibodies in first episode schizophrenia. J Neurol 2011;258:686–688.Google Scholar
15De Bot, ST, Dorresteijn, LD, Haaxma, CA et al. From psychiatric symptoms to paraneoplastic syndrome. Tijdschr Psychiatr 2008;50:603–609.Google Scholar
16Keime‐Guibert, F, Graus, F, Broet, P et al. Clinical outcome of patients with anti‐Hu‐associated encephalomyelitis after treatment of the tumor. Neurology 1999;53:1719–1723.CrossRefGoogle ScholarPubMed
17Schuler, T, Mesic, I, Madry, C et al. Formation of NR1/NR2 and NR1/NR3 heterodimers constitutes the initial step in N‐methyl‐D‐aspartate receptor assembly. J Biol Chem 2008;283:37–46.CrossRefGoogle ScholarPubMed
18Kayser, MS, Kohler, CG, Dalmau, J. Psychiatric manifestations of paraneoplastic disorders. Am J Psychiatry 2010;167:1039–1050.CrossRefGoogle ScholarPubMed
19Barry, H, Hardiman, O, Healy, DG et al. Anti‐NMDA receptor encephalitis: an important differential diagnosis in psychosis. Br J Psychiatry 2011;199:508–509.Google Scholar
20Haussleiter, IS, Emons, B, Schaub, M et al. Investigation of antibodies against synaptic proteins in a cross‐sectional cohort of psychotic patients. Schizophr Res 2012;140:258–259.Google Scholar
21Hughes, E, Peng, X, Gleichman, A et al. Cellular and synaptic mechanisms of anti‐NMDA receptor encephalitis. J Neurosci 2010;30:5866–5875.Google Scholar
22Zhang, Q, Tanaka, K, Sun, P et al. Suppression of synaptic plasticity by cerebrospinal fluid from anti‐NMDA receptor encephalitis patients. Neurobiol Dis 2012;45:610–615.Google Scholar
23Finke, C, Kopp, UA, Pruss, H et al. Cognitive deficits following anti‐NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry 2012;83:195–198.CrossRefGoogle ScholarPubMed
24Newcomer, JW, Farber, NB, Jevtovic‐Todorovic, V et al. Ketamine‐induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999;20:106–118.CrossRefGoogle Scholar
25Paparelli, A, Di Forti, M, Morrison, PD et al. Drug‐induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Front Behav Neurosci 2011;5:1.CrossRefGoogle ScholarPubMed
26Rainey, JM Jr, Crowder, MK. Prolonged psychosis attributed to phencyclidine: report of three cases. Am J Psychiatry 1975;132:1076–1078.Google Scholar
27Coyle, JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006;26:365–384.Google Scholar
28Sansing, L, Tüzün, E, Ko, M et al. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol 2007;3:291–296.Google Scholar
29Irani, S, Lang, B. Autoantibody‐mediated disorders of the central nervous system. Autoimmunity 2008;41:55–65.Google Scholar
30Irani, SR, Bien, CG, Lang, B. Autoimmune epilepsies. Curr Opin Neurol 2011;24:146–153.CrossRefGoogle ScholarPubMed
Supplementary material: File

Maat et al. supplementary material 1

Maat et al. supplementary material 1

Download Maat et al. supplementary material 1(File)
File 48.6 KB
Supplementary material: PDF

Maat et al. supplementary material 2

Maat et al. supplementary material 2

Download Maat et al. supplementary material 2(PDF)
PDF 163.7 KB